WO2000072757A1 - Microbulles a surface stabilisee intervenant dans des agents de contraste ultrasonique et agents d'apport de medicaments - Google Patents

Microbulles a surface stabilisee intervenant dans des agents de contraste ultrasonique et agents d'apport de medicaments Download PDF

Info

Publication number
WO2000072757A1
WO2000072757A1 PCT/US2000/015161 US0015161W WO0072757A1 WO 2000072757 A1 WO2000072757 A1 WO 2000072757A1 US 0015161 W US0015161 W US 0015161W WO 0072757 A1 WO0072757 A1 WO 0072757A1
Authority
WO
WIPO (PCT)
Prior art keywords
gas
microparticle
microbubble
liquid
produced
Prior art date
Application number
PCT/US2000/015161
Other languages
English (en)
Inventor
Raghuveer Basude
Margaret A. Wheatley
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Priority to AU54573/00A priority Critical patent/AU5457300A/en
Publication of WO2000072757A1 publication Critical patent/WO2000072757A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream

Definitions

  • Ultrasound contrast agents are used routinely in medical diagnostic, as well as industrial, ultrasound.
  • contrast agents are usually gas bubbles, which derive their contrast properties from the large acoustic impedance mismatch between blood and the gas contained therein.
  • Important parameters for the contrast agent include particle size, imaging frequency, density, compressibility, particle behavior (surface tension, internal pressure, bubble-like qualities), and biodistribution and tolerance.
  • Bubbles of these dimensions have resonance frequencies in the diagnostic ultrasonic range, thus improving their backscatter enhancement capabilities. Sonication has been found to be a reliable and reproducible technique for preparing standardized echo contrast agent solutions containing uniformly small microbubbles. Bubbles generated via this technique typically range in size from 1 to 15 microns in diameter with a mean bubble diameter of 6 microns (Keller et al . J. Ul trasound Med. 1986 5(9):493-8). However, the durability of these bubbles in the blood stream has been found to be limited, providing impetus for a number of approaches to further stabilize them.
  • the half -life of free microbubble solutions has been reported to range from 44 ⁇ 12 seconds for Hypaque 50%, to 253 ⁇ 73 seconds for Iopamidol .
  • Addition of a surfactant to dextrose 70 wt% has been reported to prolong bubble half life from 58 ⁇ 12 seconds to 1018 ⁇ 276 seconds (Keller et al . J " . Ul trasound Med . 1986 5(9) :493-8) .
  • WO 9847540 discloses a contrast agent for diagnostic ultrasound and targeted disease imaging and drug delivery comprising a dispersion of a biocompatible azeotropic mixture, which contains a halocarbon.
  • WO 9729783 discloses a material useful as a contrast agent which comprises an aqueous dispersion of gas microbubbles stabilized by amphiphilic material containing phospholipid molecules having an overall net charge.
  • U.S. Patent 5,695,740, U.S. Patent 5,567,415 and U.S. Patent 5,701,899 disclose a pharmaceutically acceptable ultrasound contrast agent comprising microbubbles with an internal atmosphere enhanced with a perfluorocarbon gas.
  • WO 9421301 discloses an ultrasound agent consisting of a biocompatible oil-in-water emulsion in which the oil phase comprises an oil-soluble gas/fluid or gas precursor.
  • U.S. Patent 5,637,289, U.S. Patent 5,648,062, U.S. Patent 5,827,502; and U.S. Patent 5,614,169 disclose contrast agents comprising water-soluble, microbubble generating carbohydrate microparticles, admixed with at least 20% of a non-surface active, less water-soluble material, a surfactant or an amphiphillic organic acid.
  • the agent is prepared by dry mixing, or by mixing solutions of components followed by evaporation and micronizing.
  • U.S. Patent 5,686,060 describes an injectable suspension for ultrasonic echography comprising a carrier liquid containing at least 10 7 microbubbles per milliliter and at least one saturated phospholipid at a concentration below 0.01% by weight. Also disclosed is a method of producing the suspension of air or gas filled microbubbles which comprises dissolving a surfactant and stabilizer in an organic solvent; freeze drying the solution to form a dry powder; contacting the powder with air or another gas; and admixing the powder with the aqueous carrier.
  • EP699445 describes a method of preparing a stable microbubble solution for use as an imaging agent via a surfactant mixture containing a sodium salt of saturated carboxylic acids and saponin, stearic acid, phloxine, crystal violet, polyvinyl alcohol and/or sodium laurate.
  • bubbles are formed in an aqueous solution by mixing with a machine having a 0 to 20000 rpm shaft and simultaneously introducing gas.
  • the dispersion of microbubbles produced is poured into a stopcock bottomed tube and left to stand.
  • the microbubble solution is then collected from the tube bottom and the surfactant mixture is added to change the nature of the bubble surface.
  • BR1 Stabilized sulfur hexafluoride (SF 6 ) microbubbles, referred to as BR1, have also been evaluated for use as an echo contrast agent (Schneider et al . Invest. Radiol . 1995 30 (8) :451-7) .
  • BR1 is formulated as a lyophilized product, which after addition of saline, provides a suspension containing 2 x 10 8 SF 6 microbubbles/ml with a mean diameter of 2.5 microns.
  • the use of SF 6 rather than air provides improved resistance to pressure increases such as those occurring in the left heart during systole. After reconstitution, the echogenicity and bubble characteristics remain almost constant for 8 hours.
  • BR1 injections in animals resulted in a homogenous, dose-dependent opacification of the left heart. Accordingly, BR1 is suggested to be a promising ultrasound contrast agent .
  • Micrometer-sized porous particles or "nanosponges” with properties suitable for entrapment and stabilization of the gas bubbles due to an irregular complex surface morphology have also been developed.
  • the complex morphology and surface chemistry involved in the production of these nanosponges makes it unfeasible to directly measure the volume of entrained gas (Phillips et al . Ul trasonics 1998 36 (8) : 883-892) . Accordingly, a model based on acoustic scattering principles has been proposed which indicates that only a small volume fraction of the gas should be necessary to significantly enhance the echogenicity of this type of particle-based contrast agent.
  • the effective scattering cross-section is evaluated as a function of the volume fraction of gas contained in the overall scatterer and the overall scatterer diameter.
  • the volume fraction of gas is considered as a discrete entity of single bubble.
  • the gas can be considered to be distributed throughout the particle and still arrive at a result that is similar to that for a single, discrete volume of gas.
  • the main contribution to the increased scattering cross-section is due to the compressibility difference between gas and water.
  • the backscatter coefficient is computed as the product of the resulting differential scattering cross-section and the scatterer number density. Clinical use of these nanosponges is suggested.
  • Encapsulated microbubbles typically last longer than free bubbles.
  • encapsulated microbubbles can also be used as drug delivery agents.
  • microvessel rupture caused by insonification of thin polymer-shelled microbubbles in vivo has been suggested as a minimally invasive means for delivering colloidal particles and engineered red blood cells across the endothelial lining of a targeted tissue region
  • An object of the present invention is to provide surface stabilized microbubbles.
  • the surface stabilized microbubble is produced by introducing microparticles having hydrophobic surface properties and which have been stored in a gaseous environment into a liquid so that the microparticle carries with it some gas into the liquid, thereby creating a microbubble attached to or encapsulating the microparticle .
  • the surface stabilized microbubble is produced by introducing microparticles with an affinity toward a specific gas and which have been stored in that gas into the liquid.
  • surface stabilized microbubbles are produced by insertion of a hydrophobic surface into a medium which contains a relatively hydrophobic dissolved gas such as oxygen, or nitrogen, which spontaneously comes out of solution and forms on the hydrophobic surface.
  • gas bubbles that are present or generated in the solution attach themselves to the introduced hydrophobic surface.
  • gas bubbles may be generated by a variety of methods including, but not limited to, due to agitation, homogenization, sonication, decompression, phase shift, or chemical effervescence.
  • Surface stabilized microbubbles of the present invention are useful as ultrasound contrast and drug delivery agents and to create ecogenic surfaces on objects to enhance ultrasonic detection of the object .
  • Figure 1 shows a schematic of the in vi tro apparatus used to measure the acoustic properties of the surface stabilized microparticles of the present invention.
  • a surface stabilized microbubble technique is provided to produce ultrasound contrast agents and ecogenic surfaces which enhance ultrasound detection of objects.
  • This surface stabilized microbubble technique is also useful in development of novel drug delivery systems.
  • the technique of the present invention utilizes microparticles having hydrophobic surface properties or with an affinity toward a specific gas. When a dry, relatively hydrophobic microparticle from a gaseous environment is introduced into a liquid such as buffer, water or blood, the particle carries with it some of the gas into the liquid, thereby creating a microbubble which attaches to or encapsulates the microparticle.
  • tiny gas bubbles can spontaneously form on the surface of the microparticle from the solution.
  • the gas bubble may wholly encapsulate the particle or attach/adhere itself to part of the particle.
  • microparticles can be used which have an affinity for a specific gas.
  • surface stabilized microbubbles can be created by storing microparticles with an affinity toward a specific gas in the specific gas and then introducing the microparticle into a liquid so that the microparticle carries with it some gas in which it was stored into the liquid so that a gas microbubble attaches to or encapsulates the microparticle.
  • Microparticles useful in the present invention may be solid or hollow and may comprise organic or inorganic compounds and even living components. These can include solid or hollow microparticles or surfaces of non-biodegradable polymers such as teflon, poly vinyl alcohol, polystyrene and polyethylene and biodegradable polymers such as poly anhydrides, poly esters, starch, cellulose, and ethyl cellulose.
  • the particles may include encapsulated or adhered drugs or cells such as genetically engineered cell lines which can excrete specific desired factors such as growth or necrosis factors.
  • Microparticles may be spherical or irregular in shape. However, microparticles or surface coatings used in the present invention must be partially or completely coated or made up of, at least in part, a relatively hydrophobic component. Alternatively, the microparticles or surface coatings must have an affinity for a selected gas.
  • the microbubble portion of the surface stabilized microbubble can be formed by any gas. Examples include, but are not limited to air, SF 6 , noble gases such as xenon, and PFCs.
  • a targeting moiety such as an antibody can also be attached to the surface stabilized particle.
  • surface stabilized microbubbles have backscattering characteristics which render them useful in ultrasound contrast.
  • microbubbles of the present invention were tested using equal weights (0.5 grams) of microparticles with varying hydrophobicities .
  • Specifically backscattering enhancement as a function of time was determined individually for starch (Sigma, Missouri, USA) , talc (Baby powder, CVS ,USA or Plastodent Inc. NY USA) and polyethylene (Shamrock Technologies Inc. NJ, USA) microparticles alone or in the presence of a surfactant.
  • the level of backscattering enhancement was consistent with the extent of the particle's surface hydrophobicity. Polyethylene and talc showed excellent backscattered enhancement (>30 dB) .
  • the surface stabilized microbubbles in both cases were stable at the same level of enhancement over a period of 15 minutes .
  • the enhancement of polyethylene at a dose of 0.5 grams was masked by shadowing. Hence, additional tests were carried out at lower doses of 0.05 grams and 0.02 grams .
  • the techniques of creating surface stabilized microbubbles from microparticles are also applicable to larger surfaces of objects such as radioactive seeds or biopsy needles. Using these techniques, ecogenic surfaces can be created to enhance the ultrasonic detection of the object.
  • the preferred method of in vivo administration of surface stabilized microparticulate agents is via suspension of the lyophilized particulate surface in a physiologically acceptable buffer, followed by intravenous injection just prior to conducting an ultrasound scan.
  • the microparticulates can be stored under an atmosphere of the desired gas, for example SF 6 or a PFC.
  • the needle can be coated with a hydrophobic surface, and stored sterile either under vacuum or in the presence of a gas of choice.
  • the vacuum stored object would be used under conditions where gas is expected to spontaneously form small microbubbles on the surface in si tu .
  • the seeds would be pre-coated with the hydrophobic surface and stored sterile either in vacuum or in the presence of a gas of choice .
  • Surface stabilized microbubbles are also useful in drug delivery and targeting techniques . Since the microbubbles are stabilized at the surface of a polymer or particle, this polymer/particle can comprise a matrix containing a drug by incorporation or by surface binding, or can comprise drug particle itself. Surface stabilized microbubbles comprising the drug can then be delivered to an imaged site by insonation of the surface/particle, causing the matrix to vibrate and release drug. It is also possible that the insonation will cause the particle to rupture, releasing part or all of any contents trapped within the matrix or within the hollow interior of the particle.
  • Example Acoustic properties of the surface stabilized microparticles were measured in an in-vitro setup illustrated in Figure 1.
  • An acrylic sample container (5 x 10 x 17.8 cm), having a 5 x 5 cm acoustic window (2) was filled with 750 ml of Phosphate buffer saline (PBS) ⁇ NaCl [8.01 grams], KC1 [0.194 grams], Na 2 HP0 4 [0.909 grams], and KH 2 P0 4 [0.191 grams] in one liter of water ⁇ , and placed inside the tank at approximately 30 mm from the back of the tank and 75 mm from the sides. The cover of the tank was fitted with a x-y positioning system
  • the received signals from the transducer were fed to a digital oscilloscope, (5) , (LeCroy 9350A, LeCroy Corporation, NY, USA) .
  • the digitized data from the oscilloscope were then stored and processed using Labview 4.1 (National Instruments, Austin, TX, USA) and a computer, (6) , (PowerMac 7500/132) .
  • the transducer was aligned using the X and Y axis controls to obtain maximum amplitude of the signal.
  • the transducer was then advanced towards the sample container by approximately 3 mm.
  • the focus of the transducer lay 3 mm inside the sample container, which was approximately 7.5 ⁇ sec from the front wall echo.
  • the gain of the amplifier was changed to 40 dB .
  • the backscattered enhancement was recorded at every minute for 15 minutes, post administration of the agent. The results were plotted as backscattered enhancement (dB) versus time in minutes .
  • Three agents namely, starch (Sigma) , talc ( Baby powder, CVS, USA or Plastodent Inc. NY, USA) and polyethylene microparticles (Shamrock Technologies Inc. USA) were chosen. Starch was the least hydrophobic, while polyethylene was the most hydrophobic of the three.
  • a sample (0.5 grams) of the agent to be tested was taken and the backscattered enhancement with time was recorded. The measured amount of backscattered enhancement was consistent with the hydrophobicity of the test sample .

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne des microbulles à surface stabilisée produites par des microparticules ou des objets à surface hydrophobe, et des bulles de gaz se fixant sur/encapsulant la microparticule ou le surface de l'objet. Ces microbulles et bulles de gaz sont utilisées comme agents de contraste ultrasonique ou comme agents d'apport de médicaments.
PCT/US2000/015161 1999-06-01 2000-06-01 Microbulles a surface stabilisee intervenant dans des agents de contraste ultrasonique et agents d'apport de medicaments WO2000072757A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54573/00A AU5457300A (en) 1999-06-01 2000-06-01 Surface stabilized microbubbles for use in ultrasound contrast and drug deliveryagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13696599P 1999-06-01 1999-06-01
US60/136,965 1999-06-01

Publications (1)

Publication Number Publication Date
WO2000072757A1 true WO2000072757A1 (fr) 2000-12-07

Family

ID=22475231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015161 WO2000072757A1 (fr) 1999-06-01 2000-06-01 Microbulles a surface stabilisee intervenant dans des agents de contraste ultrasonique et agents d'apport de medicaments

Country Status (2)

Country Link
AU (1) AU5457300A (fr)
WO (1) WO2000072757A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013067A2 (fr) * 2011-07-19 2013-01-24 Nuvox Pharma, L.L.C. Compositions de microbulles, leur procédé de fabrication et leur procédé d'utilisation
WO2015141917A1 (fr) * 2014-03-19 2015-09-24 서강대학교 산학협력단 Agent à double usage pour la tomographie photo-acoustique et de contraste ultrasonore lié à des nanoparticules contenant un médicament et son procédé de préparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5271928A (en) * 1990-04-02 1993-12-21 Sintetica S.A. Stable microbubbles suspensions injectable into living organisms
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141738A (en) * 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5271928A (en) * 1990-04-02 1993-12-21 Sintetica S.A. Stable microbubbles suspensions injectable into living organisms

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013067A2 (fr) * 2011-07-19 2013-01-24 Nuvox Pharma, L.L.C. Compositions de microbulles, leur procédé de fabrication et leur procédé d'utilisation
WO2013013067A3 (fr) * 2011-07-19 2013-04-04 Nuvox Pharma, L.L.C. Compositions de microbulles, leur procédé de fabrication et leur procédé d'utilisation
US10279053B2 (en) 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same
WO2015141917A1 (fr) * 2014-03-19 2015-09-24 서강대학교 산학협력단 Agent à double usage pour la tomographie photo-acoustique et de contraste ultrasonore lié à des nanoparticules contenant un médicament et son procédé de préparation
KR20150109064A (ko) * 2014-03-19 2015-10-01 (주)아이엠지티 약물을 함유한 나노입자가 결합된 이중-목적 paｔ／초음파 조영제 및 이의 제조방법
KR101595795B1 (ko) 2014-03-19 2016-02-22 (주)아이엠지티 약물을 함유한 나노입자가 결합된 이중-목적 paｔ／초음파 조영제 및 이의 제조방법
US10912848B2 (en) 2014-03-19 2021-02-09 Imgt Co, Ltd. Dual-purpose PAT/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same

Also Published As

Publication number Publication date
AU5457300A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
JP4837663B2 (ja) 造影画像化のためのガス充填微小胞組成物
CA2214778C (fr) Methode pour la production de microparticules polymeriques; microparticules ainsi produites et leur utilisation a des fins de diagnostics medicaux
US5560364A (en) Suspended ultra-sound induced microbubble cavitation imaging
US8715622B2 (en) Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US5352436A (en) Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same
Wheatley et al. Comparison of in vitro and in vivo acoustic response of a novel 50: 50 PLGA contrast agent
US20060013771A1 (en) Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging
US20040258760A1 (en) Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
CN101977634A (zh) 合成空心球的方法
JP5015606B2 (ja) モレキュラーイメージング用の超音波造影剤
EP1164936B1 (fr) Procede de mesure de la pression de fluide ambiante
EP1390016B1 (fr) Microcapsules et nanocapsules polymères échogéniques et procédés de production et d'utilisation
US20100221190A1 (en) Method for producing a particle comprising a gas core and a shell and particles thus obtained
CA2248739A1 (fr) Microparticules, procede permettant de les produire et leur utilisation pour les diagnostics effectues a l'aide d'ultrasons
AU2002307056A1 (en) Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
WO2000072757A1 (fr) Microbulles a surface stabilisee intervenant dans des agents de contraste ultrasonique et agents d'apport de medicaments
Deng Development and characterization of a contrast agent for diagnostic ultrasound: polymer-coated microcapsules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09980134

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP